Deerfield Management’s Achilles Therapeutics ACHL Stock Holding History

Deerfield Management’s Portfolio ACHL Stock Details ACHL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-301,431	Closed	-$2.95M	–	157
2021 Q2	$2.95M	Sell	301,431 -498,569	-62%	-$6.76M	0.05%	135
2021 Q1	$13.2M	Buy	+800,000	New	+$13.2M	0.28%	89

Other funds holding ACHL

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Point72 Asset Management

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Deerfield Management's ACHL Position: Q3 2021 in Review

Deerfield Management sold out of Achilles Therapeutics (ACHL) in Q3 2021, closing a stake of 301,431 shares — an estimated $2.95M sold.

Deerfield Management first reported a position in ACHL in Q1 2021 and held it in 2 quarters. The position peaked at $13.2M in Q1 2021. 20 funds tracked by Wall St. Rank hold ACHL as of Q3 2021.

Deerfield Management reported no remaining Achilles Therapeutics position as of Q3 2021 after selling out during the quarter.
Deerfield Management sold 301,431 Achilles Therapeutics shares in Q3 2021, an estimated $2.95M.
Deerfield Management first reported a position in Achilles Therapeutics in Q1 2021 and held it in 2 quarters.
Deerfield Management's Achilles Therapeutics position peaked at $13.2M in Q1 2021.
20 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q3 2021.

Based on Deerfield Management's 13F filing for Q3 2021, filed 15 Nov 2021.